Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Sickle Cell Disease
Interventions: Haploidentical Bone Marrow Transplantation, Hydroxyurea, Rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, Mesna; Procedure · Drug · Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 45 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 32
States / cities: Birmingham, Alabama • Oakland, California • Aurora, Colorado + 24 more

Conditions: Sickle Cell Disease, Chronic Pain
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 100 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sickle Cell Disease
Interventions: mHealth app + booklets; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Chicago, Illinois • St Louis, Missouri • Columbus, Ohio + 1 more

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years and older
Enrollment: 297 participants
Timeline: 2021 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Wilmington, Delaware • St. Petersburg, Florida + 8 more

Conditions: Acute Chest Syndrome, Sickle Cell Disease
Interventions: Point of Care Ultrasound; Device
Lead sponsor: Indiana University; Other
Eligibility: Up to 25 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sickle Cell Disease
Interventions: Cannabis; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sickle Cell Anemia, Pulmonary Hypertension
Interventions: Nitric Oxide, INO Pulse - NO Delivery System; Drug · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Steroid arm, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Anemia
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: New Orleans, Louisiana • Memphis, Tennessee

Conditions: Sickle Cell Disease
Interventions: Cyclophosphamide 50mg, Abatacept, Alemtuzumab, Hydroxyurea, Thiotepa, Filgrastim, Sirolimus, Azathioprine, TBI, Hematopoietic Progenitor Cell Infusion; Drug · Radiation · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Prematurity, Neurodevelopmental Disorder, Carnitine Deficiency
Interventions: L-carnitine, 5% Dextrose; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 1 Day to 3 Days
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Genetic Differences of Lipid Metabolism/Healthy Subjects
Interventions: soybean oil and borage oil; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sickle Cell Disease, Asthma, Acute Chest Syndrome
Interventions: Budesonide inhalation suspension; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 1 Year to 4 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions: Ketamine; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 10 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Oakland, California

Conditions: Sickle Cell Disease
Interventions: Interview; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years and older
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cardiovascular Diseases, Myocardial Infarction, Heart Diseases, Death, Sudden, Cardiac
Interventions: Cardiopulmonary Resuscitation, Automatic External Defibrillation; Other · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 7,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 7 Years to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Hartford, Connecticut • Baltimore, Maryland

Conditions: Sickle Cell Disease
Interventions: Pociredir; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 8
States / cities: Little Rock, Arkansas • Los Angeles, California • Baton Rouge, Louisiana + 5 more

Conditions: Sickle Cell Anemia
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 8 Years to 20 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina

Conditions: Sickle Cell Disease
Interventions: Hematopoietic Stem Cell Transplantation, CliniMACS, See intervention description; Procedure · Device · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 16 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Pain Crisis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 90 Years
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Sickle Cell Disease Without Crisis
Interventions: Plerixafor; Drug
Lead sponsor: Alessandra Biffi; Other
Eligibility: 18 Years to 35 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease
Interventions: Prasugrel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 20
States / cities: Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more

Search by objective public record fields.

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Use of a Mobile-based App for SCD Patients

Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease

Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

Ultrasound Acute Chest Syndrome Sickle Cell Disease

Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

Steroid Treatment for Sickle Cell Pain Crisis

Sickle Cell Disease: A Retrospective Chart Review

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants

Botanical Oils Study to Determine Genetic Differences in the Way Your Body Processes Fats in Edible Oils

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)

Home Use of Automatic External Defibrillators to Treat Sudden Cardiac Arrest

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

Assessing Function in Pediatric Patients With Sickle Cell Disease

Open-Label Extension Study to Pioneer Study 6058-SCD-101

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound

Natural History of Sickle Cell Disease

Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)